following a full submission assessed under the orphan equivalent process:
ruxolitinib phosphate (Jakavi®) is accepted for use within NHSScotland.
Indication under review: The treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea (hydroxycarbamide).
Ruxolitinib was superior to best available therapy in two phase III studies in patients with polycythaemia vera who were resistant to or intolerant of hydroxycarbamide, with or without splenomegaly.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a list price that is equivalent or lower.
This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.
- Medicine name:
- ruxolitinib (Jakavi)
- SMC ID:
The treatment of adult patients with polycythaemia vera (PV) who are resistant to or intolerant of hydroxyurea (HU).
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published
- 09 December 2019